ImmunityBio (NasdaqGS:IBRX) presented new clinical data on ANKTIVA in advanced non small cell lung cancer and BCG unresponsive non muscle invasive bladder cancer at the 2026 ASCO Annual Meeting. The ...

ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced two poster presentations and one ...

ImmunityBio's stock is moving higher after the FDA announced it would review a possible label expansion for the company's ...

Detailed price information for Immunitybio Inc (IBRX-Q) from The Globe and Mail including charting and trades.

Dr. Patrick Soon-Shiong, executive chairman of ImmunityBio, said research from Washington State University shows the virus ...

Detailed price information for Immunitybio Inc (IBRX-Q) from The Globe and Mail including charting and trades.

Lawyers at Kahn Swick & Foti, LLC are available to discuss your legal options. About the Lawsuit ImmunityBio and certain of its executives are charged with failing to disclose material information ...

The cytokine interleukin-15 (IL-15) plays a crucial role in the immune system by affecting the development, maintenance, and function of key immune cells—NK and CD8+ killer T cells—that are involved ...

The cytokine interleukin-15 (IL-15) plays a crucial role in the immune system by affecting the development, maintenance, and function of key immune cells—NK and CD8+ killer T cells—that are involved ...

ImmunityBio’s (IBRX) meteoric rise this year has forced short sellers betting against the cancer drug developer to record roughly $492M in paper losses in the first 12 trading days of 2026, Bloomberg ...

Cancer-focused biotech ImmunityBio (NASDAQ: IBRX) hasn't been in the good graces of a top regulator lately, and the latest development in that story on Monday was discouraging for investors. Numerous ...

ImmunityBio Inc. IBRX stock is up during Wednesday’s premarket session as the company is gaining attention following the FDA’s acceptance of its supplemental Biologics License Application (sBLA) for ...